Featured

Watch as Canada turns blue in September. Landmarks and homes glow in solidarity, raising awareness and showing support for those affected by prostate cancer. A big thank you to all of the landmarks, homes and proclamations from all across the country that are supporting our awareness campaign.

Join Prostate Cancer Foundation Canada online for their free Prostate Cancer Awareness Month speaker series.

Prostate cancer touches 1 in 8 Canadian men. Paddle Battle for Prostate turns passion for the game into a force for change — uniting communities in Vancouver, Toronto, and Moncton on the court and in the cause. Whether you play or give, your presence matters.

On September 25, 2026, KDocsFF and Salt City Advocacy are hosting an in-person community dialogue dedicated to breaking down barriers around prostate health awareness and prevention. Held at Kwantlen Polytechnic University's Surrey Conference Centre, this three-hour event brings together survivors, advocates, health professionals, and community members for honest, open discussions about what it means to prioritize men's wellness. This kind of dialogue is essential—especially when we consider that Black Canadian men face disproportionately higher rates of prostate cancer diagnosis and mortality. Creating safe spaces to talk, learn, and connect isn't just helpful; it's lifesaving.

National Cancer Survivors Day® is celebrated each year on the first Sunday in June. In 2026, NCSD took place on June 7. The Canadian Cancer Survivor Network marked the day by receiving a proclamation in Ottawa by Mayor Sutcliffe.

Manitobans can now purchase a Manitoba Motorcycle Ride for Dad specialty licence plate, with each sale supporting the fight against prostate cancer. Released by Manitoba Public Insurance (MPI) on Monday, the $70 licence plate is available at any Autopac agent—with $30 from each plate going to the Manitoba Prostate Cancer Support Group.

As of July 2, 2025, Pluvicto® (lutetium (177Lu) vipivotide tetraxetan injection) is publicly reimbursed in Quebec for eligible patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

Astellas Pharma Canada, Inc. announced that XTANDI® (enzalutamide) is now funded by the Ontario Drug Benefit Program under the Exceptional Access Program for the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence (BCR) at high risk of metastasis (high-risk BCR).i This decision means XTANDI is now publicly reimbursed in Ontario for all of its approved prostate cancer indications.

CCSN hosted a virtual prostate cancer patient focus group to gain insights on the experiences of individuals receiving treatment for prostate cancer, focusing on management approaches, side effects, and overall impact on quality of life. It was also discussed how we could identify strategies to optimize support for those living with prostate cancer.

Effective February 1, 2025, Nova Scotia is publicly funding Pluvicto, a targeted radioligand therapy. -Published on February 3rd 2025

Scientists have developed a spit test that could “turn the tide” on prostate cancer worldwide by spotting the disease earlier, detecting where men are at high risk and sparing others unnecessary treatment.

Not only do participants enjoy participating in great physical activity, but the study also showed the positive impact on men’s psychosocial wellbeing as being even more important. And to this I personally attest.